Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
24.36 (1y: +91%)
Market Cap 1.11 B P/E(ttm)
Enterprise Value 803.24 M P/B 3.80
INFI- NAS (USA)
Infinity Pharmaceuticals, Inc.
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$24.36
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry		 vs
history
Cash to Debt No Debt
INFI's Cash to Debt is ranked lower than
68% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. INFI: No Debt )
INFI' s 10-Year Cash to Debt Range
Min: 0.93   Max: 11822.4
Current: No Debt
0.93
11822.4
Equity to Asset 0.924
INFI's Equity to Asset is ranked lower than
87% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 0.54 vs. INFI: 0.924 )
INFI' s 10-Year Equity to Asset Range
Min: 0.06   Max: 0.92
Current: 0.92
0.06
0.92
F-Score: 2
Z-Score: 3.3
M-Score: -6.34
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry		 vs
history
Operating margin (%) -112.10
INFI's Operating margin (%) is ranked lower than
286533% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -52.55 vs. INFI: -112.10 )
INFI' s 10-Year Operating margin (%) Range
Min: -155.8   Max: 22.9
Current: -112.1
-155.8
22.9
Net-margin (%) -114.5
INFI's Net-margin (%) is ranked lower than
286533% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -55.70 vs. INFI: -114.5 )
INFI' s 10-Year Net-margin (%) Range
Min: -153.8   Max: 28.3
Current: -114.5
-153.8
28.3
ROE (%) -17.4
INFI's ROE (%) is ranked lower than
286533% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -16.60 vs. INFI: -17.4 )
INFI' s 10-Year ROE (%) Range
Min: -259.5   Max: 19.7
Current: -17.4
-259.5
19.7
ROA (%) -16.1
INFI's ROA (%) is ranked lower than
286533% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -14.40 vs. INFI: -16.1 )
INFI' s 10-Year ROA (%) Range
Min: -59.5   Max: 14.7
Current: -16.1
-59.5
14.7
Revenue Growth (%) -5.9
INFI's Revenue Growth (%) is ranked lower than
286533% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. INFI: -5.9 )
INFI' s 10-Year Revenue Growth (%) Range
Min: -38.2   Max: 21.1
Current: -5.9
-38.2
21.1
EBITDA Growth (%) -2.1
INFI's EBITDA Growth (%) is ranked lower than
286533% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -11.35 vs. INFI: -2.1 )
INFI' s 10-Year EBITDA Growth (%) Range
Min: -40.8   Max: 14.1
Current: -2.1
-40.8
14.1
EPS Growth (%) 8
INFI's EPS Growth (%) is ranked lower than
95% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -8.70 vs. INFI: 8 )
INFI' s 10-Year EPS Growth (%) Range
Min: -31.9   Max: 20.9
Current: 8
-31.9
20.9
ยป INFI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

INFI Guru Trades in Q2 2012

Jim Simons 242,275 sh (+48.38%)
Jean-Marie Eveillard Sold Out
» More
Q3 2012

INFI Guru Trades in Q3 2012

Jim Simons 192,775 sh (-20.43%)
» More
Q4 2012

INFI Guru Trades in Q4 2012

George Soros 75,000 sh (New)
Louis Moore Bacon 125,000 sh (New)
Steven Cohen 790 sh (New)
Jim Simons 403,800 sh (+109.47%)
» More
Q1 2013

INFI Guru Trades in Q1 2013

RS Investment Management 168,200 sh (New)
Steven Cohen 513,701 sh (+64925.4%)
Jim Simons 481,700 sh (+19.29%)
Louis Moore Bacon Sold Out
George Soros 40,000 sh (-46.67%)
» More
» Details

Insider Trades

Latest Guru Trades with INFI

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2013-03-31 Reduce -46.67%0.01%$32.93 - $49.37 $ 24.36-38%40000
George Soros 2012-12-31 New Buy0.03%$17.74 - $35.04 $ 24.36-4%75000
Jean-Marie Eveillard 2012-06-30 Sold Out 0.01%$11.71 - $13.76 $ 24.3691%0
Jean-Marie Eveillard 2012-03-31 Reduce -54.94%0.01%$5.9781 - $12.16 $ 24.36206%180000
Jean-Marie Eveillard 2011-09-30 Reduce -25.85%0.01%$6.17 - $10.36 $ 24.36210%464241
Wilbur Ross 2011-06-30 Sold Out $5.61 - $8.19 $ 24.36273%0
Wilbur Ross 2010-12-31 Reduce -63.91%0.02%$5.12 - $6.86 $ 24.36297%7415
Jean-Marie Eveillard 2010-12-31 Add 60.34%0.01%$5.12 - $6.86 $ 24.36297%585437
Wilbur Ross 2010-09-30 Reduce -25.39%0.01%$4.62 - $6.3 $ 24.36342%20545
Jean-Marie Eveillard 2010-09-30 Add 29.72%$4.62 - $6.3 $ 24.36342%365123
Jean-Marie Eveillard 2010-06-30 Add 566.95%0.01%$5.88 - $7.94 $ 24.36270%281460
Premium More recent guru trades are included for Premium Members only!!

Ratios

vs
industry		 vs
history
P/B 3.80
INFI's P/B is ranked lower than
278551% of the 359 Companies
in the Global Biotechnology industry.

( Industry Median: 3.70 vs. INFI: 3.80 )
INFI' s 10-Year P/B Range
Min: 0.45   Max: 51.23
Current: 3.8
0.45
51.23
P/S 40.98
INFI's P/S is ranked lower than
255102% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 7.53 vs. INFI: 40.98 )
INFI' s 10-Year P/S Range
Min: 1.1   Max: 14.27
Current: 40.98
1.1
14.27
EV-to-EBIT 3.2
INFI's EV-to-EBIT is ranked lower than
375939% of the 266 Companies
in the Global Biotechnology industry.

( Industry Median: 21.21 vs. INFI: 3.2 )
INFI' s 10-Year EV-to-EBIT Range
Min: 0.3   Max: 493.6
Current: 3.2
0.3
493.6

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 3.9
INFI's Price/Net Cash is ranked lower than
529100% of the 189 Companies
in the Global Biotechnology industry.

( Industry Median: 9.50 vs. INFI: 3.9 )
INFI' s 10-Year Price/Net Cash Range
Min: 0.9   Max: 38.4
Current: 3.9
0.9
38.4
Price/Net Current Asset Value 121.8
INFI's Price/Net Current Asset Value is ranked lower than
319488% of the 313 Companies
in the Global Biotechnology industry.

( Industry Median: 41.90 vs. INFI: 121.8 )
INFI' s 10-Year Price/Net Current Asset Value Range
Min: 2.9   Max: 884
Current: 121.8
2.9
884
Price/Tangible Book 3.7
INFI's Price/Tangible Book is ranked lower than
290697% of the 344 Companies
in the Global Biotechnology industry.

( Industry Median: 4.90 vs. INFI: 3.7 )
INFI' s 10-Year Price/Tangible Book Range
Min: 0.7   Max: 15.2
Current: 3.7
0.7
15.2
Price/Median PS Value 2.7
INFI's Price/Median PS Value is ranked lower than
289017% of the 346 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. INFI: 2.7 )
INFI' s 10-Year Price/Median PS Value Range
Min: 0.6   Max: 2.9
Current: 2.7
0.6
2.9
Earnings Yield (Greenblatt) 31.50
INFI's Earnings Yield (Greenblatt) is ranked lower than
446428% of the 224 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. INFI: 31.50 )
INFI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 301.4
Current: 31.5
0.2
301.4
Forward Rate of Return (Yacktman) -2.18
INFI's Forward Rate of Return (Yacktman) is ranked lower than
1492536% of the 67 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. INFI: -2.18 )
INFI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -19.5   Max: 15.6
Current: -2.18
-19.5
15.6

Business Description

Infinity Pharmaceuticals, Inc was incorporated in California on March 22, 1995 under the name IRORI and, in 1998, the Company changed its name to Discovery Partners International, Inc., or DPI. On September 12, 2006, DPI completed a merger with Infinity Pharmaceuticals, Inc., or IPI, to which a wholly-owned subsidiary of DPI merged with and into IPI. IPI was the surviving corporation in the merger, changed its name to Infinity Discovery, Inc., or IDI, and became a wholly owned subsidiary of DPI. The Company changed its corporate name from Discovery Partners International, Inc. to Infinity Pharmaceuticals, Inc. The Company discovers, develops, and delivers medicines for the treatment of cancer and related conditions. The Company's lead product candidate is saridegib, also known as IPI-926, a novel, potent, oral molecule that inhibits the Hedgehog pathway by binding to the Smoothened receptor, a protein that plays a critical role in the malignant activation of the Hedgehog pathway. The Company is evaluating saridegib in a randomized, double-blind Phase 2 clinical trial to assess the safety and efficacy of saridegib compared to placebo in approximately 140 patients with metastatic or locally advanced, inoperable chondrosarcoma. The Company is also enrolling patients in an exploratory Phase 2 clinical trial evaluating the safety and efficacy of saridegib in patients with myelofibrosis. Retaspimycin hydrochloride (HCl), also known as IPI-504, is a novel, potent and selective inhibitor of heat shock protein 90, or Hsp90. Cancer cells depend on Hsp90 to maintain many proteins critical for cancer growth, proliferation and survival in a functional state. Retaspimycin HCl is currently being evaluated in a randomized, double-blind Phase 2 clinical trial in combination with docetaxel, a chemotherapy, compared to placebo and docetaxel in approximately 200 patients with second- or third-line non-small cell lung cancer, or NSCLC, who are naive to docetaxel treatment and have a history of heavy smoking. The Company is also enrolling patients in a Phase 1b/2 trial to explore the safety and efficacy of retaspimycin HCl in combination with everolimus, an mTOR inhibitor, in NSCLC patients with a KRAS mutation. The Company's lead compound in this PI3K Inhibitor Program is IPI-145, a potent, orally-available inhibitor of PI3K-delta and PI3K-gamma. PI3Ks, are a family of enzymes involved in key immune cell functions, including cell proliferation and survival, cell differentiation, and cellular trafficking. PI3K-delta and PI3K-gamma, two isoforms of PI3K, play key roles in inflammatory and autoimmune diseases. Government authorities in the United States and in other countries extensively regulate, among other things, the research, development, testing, manufacturing, storage, recordkeeping, approval, promotion, labeling, advertising, distribution, marketing, post-approval monitoring and reporting, sampling, and export and import of pharmaceutical produc
Company Website
SEC Reports
Industry: Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG
Traded in other countries:I3F.Germany
ยป More Articles for INFI

Headlines

Articles On GuruFocus.com
My 3 Favorite Dividend Stocks at All-Time-Highs | Stock List Dec 27 2012 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q/A) Mar 15 2011 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q/A) Mar 15 2011 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q/A) Mar 15 2011 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q) Aug 04 2010 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q) May 06 2010 
Opportunistic Coat-tailing Jan 05 2010 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q) Aug 06 2009 
Infinity Pharmaceuticals Inc. Reports Operating Results (10-Q) May 06 2009 


Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial